- Stage of development
-
Pre-clinical in vivo
- Intellectual property
-
PCT application
- Intended collaboration
-
Licensing and/or co-development
- Contact
-
Eva GabaldónVice-presidency for Innovation and Transfereva.gabaldon@csic.escomercializacion@csic.es
- Reference
-
CSIC/EG/125
Additional information
#Biotechnology
#Molecular and cell biology
#Agriculture, livestock and marine science
#Animal health
Vaccine for the prevention of anaplasmosis
Recombinant chimeric antigen used for the prevention or treatment of infections caused by Anaplasma phagocytophilum.
- Market need
-
Anaplasma phagocytophilum (Rickettsiales: Anaplasmataceae) is a tick-borne intracellular pathogen that is present in many regions of the world, causing human granulocytic anaplasmosis, tick-borne fever and canine anaplasmosis. Infection with this bacterium has been documented in a wide range of hosts including cattle, goats, sheep, horses, dogs, humans, roe deer, deer and various rodents.
- Proposed solution
-
By searching for and characterizing protective epitopes or immunological quantum, it has been designed and produced chimeric protective antigens that protect MSP4 against A. phagocytophilum in sheep and rabbits in order to develop an effective vaccine against anaplasmosis.
- Competitive advantages
-
- Effective vaccine candidate for the control of anaplasmosis.
- The design of chimeric antigens allows a more efficient epitope recognition by the immune system.
- This chimera allows that peptide from MSP4 to be protective against A. phagocytophylum in different hosts.
- This vaccine is environmentally friendly by antibiotic use and constitutes the safest and effective intervention.